Chicago Equity Partners’s Regenxbio RGNX Stock Holding History

Chicago Equity Partners’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-5,605	Closed	-$200K	–	944
2019 Q3	$200K	Hold	5,605	–	–	0.01%	837
2019 Q2	$288K	Sell	5,605 -6,310	-53%	-$315K	0.01%	812
2019 Q1	$683K	Sell	11,915 -29,830	-71%	-$1.48M	0.03%	602
2018 Q4	$1.75M	Sell	41,745 -18,505	-31%	-$1.09M	0.07%	362
2018 Q3	$4.55M	Buy	60,250 +15,724	+35%	+$1.13M	0.13%	202
2018 Q2	$3.19M	Buy	+44,526	New	+$2.13M	0.1%	292

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Chicago Equity Partners's RGNX Position: Q4 2019 in Review

Chicago Equity Partners sold out of Regenxbio (RGNX) in Q4 2019, closing a stake of 5,605 shares — an estimated $200K sold.

Chicago Equity Partners first reported a position in RGNX in Q2 2018 and held it in 6 quarters. The position peaked at $4.55M in Q3 2018. 187 funds tracked by Wall St. Rank hold RGNX as of Q4 2019.

Chicago Equity Partners reported no remaining Regenxbio position as of Q4 2019 after selling out during the quarter.
Chicago Equity Partners sold 5,605 Regenxbio shares in Q4 2019, an estimated $200K.
Chicago Equity Partners first reported a position in Regenxbio in Q2 2018 and held it in 6 quarters.
Chicago Equity Partners's Regenxbio position peaked at $4.55M in Q3 2018.
187 funds tracked by Wall St. Rank held Regenxbio as of Q4 2019.

Based on Chicago Equity Partners's 13F filing for Q4 2019, filed 10 Feb 2020.